Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Immunogen Inc patents (2016 archive)


Recent patent applications related to Immunogen Inc. Immunogen Inc is listed as an Agent/Assignee. Note: Immunogen Inc may have other listings under different names/spellings. We're not affiliated with Immunogen Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunogen Inc-related inventors


Cytotoxic benzodiazepine derivatives

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (i)-(vii). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. ... Immunogen Inc

Drug conjugate composition

The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.. ... Immunogen Inc

Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same

The present invention relates to antibodies that bind cd33. More particularly, the invention relates to anti-cd33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. ... Immunogen Inc

Ca6 antigen-specific cytotoxic conjugate and methods of using the same

Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the ca6 glycotope. ... Immunogen Inc

Cd37-binding molecules and immunoconjugates thereof

Methods of using cd37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to cd37 to deplete b-cells (e.g., non-cancerous b-cells) and methods of treating autoimmune and inflammatory diseases are further provided.. . ... Immunogen Inc

Cd37-binding molecules and immunoconjugates thereof

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to cd37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.. ... Immunogen Inc

Methods of preparation of conjugates

The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.. ... Immunogen Inc

Methods for the preparation of charged crosslinkers

Processes for the preparation of charged crosslinkers bearing a sulfonic acid moiety are disclosed. These procedures also optionally include methods to convert the resulting products to substantially a single salt form.. ... Immunogen Inc

Novel maytansinoid derivatives with peptide linker and conjugates thereof

The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (i). The invention also provides novel cytotoxic agents of formula (ii), linker compounds represented by formula (iii), and drug-linker compounds represented by formula (iv). ... Immunogen Inc

Novel benzodiazepine derivatives

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (i) and (ii), in which the diazepine ring (b) is fused with a heterocyclic ring (cd), wherein the heterocyclic ring is bicyclic or a compound of formula (iii), in which the diazepine ring (b) is fused with a heterocyclic ring (c), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. ... Immunogen Inc

Diagnostic assays and kits for detection of folate receptor 1

The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.. ... Immunogen Inc

Purification of intermediates used in the preparation of heterobifunctional linkers

The present invention is directed to a method of separating a monocarboxylic represented by the following stmctural formula: (i) from a dicarboxylic acid represented by the following structural fonnula: (ii) using silica chromatography.. . ... Immunogen Inc

Cd20 antibodies and uses thereof

Cd20 is a transmembrane protein of the tetra-spanin family expressed on the surface of b-cells from peripheral blood as well as lymphoid tissues. Cd20 expression persists from the early pre-b cell stage until the plasma cell differentiation stage. ... Immunogen Inc

Potent conjugates and hydrophilic linkers

Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. ... Immunogen Inc

04/07/16 / #20160096888

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.. ... Immunogen Inc

04/07/16 / #20160096887

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.. ... Immunogen Inc

04/07/16 / #20160095938

Conjugates comprising cell-binding agents and cytotoxic agents

The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (cba) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the cba. The invention also provides methods of preparing the conjugates of the present invention. ... Immunogen Inc

03/24/16 / #20160083471

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.. ... Immunogen Inc

03/24/16 / #20160082114

Cytotoxic benzodiazepine derivatives

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (i)-(vi). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. ... Immunogen Inc

03/17/16 / #20160075781

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.. ... Immunogen Inc

03/03/16 / #20160060345

Novel egfr-binding molecules and immunoconjugates thereof

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to egfr are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.. ... Immunogen Inc

03/03/16 / #20160060339

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.. ... Immunogen Inc

03/03/16 / #20160058884

Methods for formulating antibody drug conjugate compositions

The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“adc”) that reduce potency variability between batches of adc and provide administration of such therapeutic compositions within a narrow intended range.. . ... Immunogen Inc

03/03/16 / #20160058882

Cytotoxic agents comprising new ansamitocin derivatives

New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. ... Immunogen Inc

02/18/16 / #20160045616

Process for preparing purified drug conjugates

The invention provides processes for preparing a cell-binding agent chemically coupled to a drug. A first process comprises covalently attaching a linker to a cell-binding agent, an optional purification step, conjugating a drug to the cell-binding agent, a subsequent purification step, and optional holding steps. ... Immunogen Inc

02/04/16 / #20160031902

Novel maytansinoid derivatives with sulfoxide linker

The invention relates to novel maytansinoid compounds having sulfoxide linkers and more specifically to novel maytansinoid compounds of structural formula (i) and (ii). The invention also provides conjugates of the maytansinoid compounds linked to a cell-binding agent. ... Immunogen Inc

01/21/16 / #20160017053

Non-antagonistic egfr-binding molecules and immunoconjugates thereof

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to egfr are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.. ... Immunogen Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunogen Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunogen Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###